Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning

References

• BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• CATT Research GroupMartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• StewartMWRosenfeldPJPredicted biological activity of intravitreal VEGF TrapBr J Ophthalmol200892566766818356264
   PubMed Web of Science ®Google Scholar
• BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAm J Ophthalmol201315611522.e123706500
   PubMed Web of Science ®Google Scholar
• ChoHShahCPWeberMHeierJSAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumabBr J Ophthalmol20139781032103523766432
   PubMed Web of Science ®Google Scholar
• FerronePJAnwarFNaysanJEarly initial clinical experience with intravitreal aflibercept for wet age-related macular degenerationBr J Ophthalmol201498Suppl 1i17i2124795335
   PubMed Web of Science ®Google Scholar
• KumarNMarsigliaMMrejenSVisual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degenerationRetina20133381605161223549101
   PubMed Web of Science ®Google Scholar
• MessengerWBCampbellJPFaridiAInjection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degenerationBr J Ophthalmol20149891205120724795334
   PubMed Web of Science ®Google Scholar
• WykoffCCBrownDMMaldonadoMECroftDEAflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)Br J Ophthalmol201498795195524518078
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol200914814358.e119376495
   PubMed Web of Science ®Google Scholar
• YanuzziLARetinal histologyThe Retinal AtlasPhiladelphia, PASaunders201024
   Google Scholar
• ArnoldJJCampainABarthelmesDFight Retinal Blindness Study GroupTwo-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degenerationOphthalmology201512261212121925846847
   PubMed Web of Science ®Google Scholar
• InoueMYamaneSSatoSSakamakiKArakawaAKadonosonoKComparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degenerationAm J Ophthalmol20161699510327320059
   PubMed Web of Science ®Google Scholar
• RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
   PubMed Web of Science ®Google Scholar
• OtaniATakagiHOhHVascular endothelial growth factor family and receptor expression in human choroidal neovascular membranesMicrovasc Res200264116216912074642
   PubMed Web of Science ®Google Scholar
• RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci20034473186319312824270
   PubMed Web of Science ®Google Scholar
• MiyamotoNde KozakYJeannyJCPlacental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathyDiabetologia200750246147017187248
   PubMed Web of Science ®Google Scholar
• Cunha-VazJBernardesRLoboCBlood-retinal barrierEur J Ophthalmol201021Suppl 6S3S9
   Google Scholar
• GharbiyaMCrucianiFMariottiCGrandinettiFMarencoMCacaceVChoroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus afliberceptJ Ocul Pharmacol Ther201531635736226133059
   PubMed Web of Science ®Google Scholar
• KoizumiHKanoMYamamotoAShort-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degenerationAm J Ophthalmol2015159462763325555799
   PubMed Web of Science ®Google Scholar
• PatelKHChowCCRathodRRapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumabEye (Lond)2013275663667 quiz 66823558214
   PubMed Web of Science ®Google Scholar
• BroadheadGKHongTZhuMResponse of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degenerationRetina201535597598125627086
   PubMed Web of Science ®Google Scholar